<DOC>
	<DOCNO>NCT01122719</DOCNO>
	<brief_summary>To evaluate safety efficacy Janus OPTIMA Tacrolimus-Eluting Stent ( Optima TES , CID ) treatment de novo coronary lesion associate short-term ( two month ) dual antiplatelet ( aspirin + clopidogrel ) regimen .</brief_summary>
	<brief_title>Brazilian Italian Evaluation Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen</brief_title>
	<detailed_description>The present study post-market , prospective , international , two-center , single arm study involve 60 patient single , de novo non-complex coronary lesion . Enrolled patient ask return follow-up clinical evaluation 1 , 6 , 12 24 month . At 3 month additional follow-up phone contact . Furthermore , first 15 patient undergo angiographic OCT follow-up two month . The remain 45 patient undergo angiographic IVUS follow-up 8 month .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient &gt; 18 year age ; Symptoms stable unstable angina and/or presence positive functional test ischemia ; Presence single de novo target lesion locate native coronary vessel suitable percutaneous treatment study stent ; Acceptable candidate coronary artery bypass graft ( CABG ) surgery ; The subject willing sign write informed consent prior procedure , willing undergo ALL study protocol followup , include angiographic , IVUS OCT assessment . Single , de novo lesion Target lesion locate major epicardial coronary vessel reference 2.53.5mm diameter ( online QCA ) Target lesion ≤19mm length ( visual estimation ) treat ( cover ) one single study stent ( 19 24mm length ) ; ≥50 % &lt; 100 % diameter stenosis ; TIMI ( Thrombolysis In Myocardial Infarction ) flow grade ≥2 . Known hypersensitivity contraindication tacrolimus , heparin , require medication include thienopyridines , contrast medium adequately pre medicate ; Patient female childbearing potential ; Pretreatment target lesion device balloon angioplasty ; Previous brachytherapy target vessel ; Presence nontarget vessel lesion require staged procedure ( ) &lt; 30 day index procedure ; Prior CABG surgery target vessel ; Previous percutaneous coronary intervention ( PCI ) CABG surgery &lt; 30 day index procedure date ; Acute myocardial infarction &lt; 3 day , cardiac enzyme elevation include total creatine kinase ( CK ) &gt; 2 time upper normal limit value and/or CKMB upper normal limit value within past 72 hour ; CK and/or CKMB level elevate upper normal limit value time index procedure ; Documented leave ventricular ejection fraction &lt; 30 % ; Renal insufficiency determine baseline serum creatinine &gt; 2.0 mg/dl ; Thrombocytopenia baseline platelet count &lt; 100,000 cells/mm3 ; Anemia baseline hemoglobin &lt; 10g/dL ; Extensive peripheral vascular disease extreme anticoagulation precludes safe &gt; 5 French sheath insertion ; History bleed diathesis , coagulopathy , refusal blood transfusion ; Patients suffer stroke , transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) within past 6 month ; Significant gastrointestinal genitourinary bleed within past 6 month ; Patient recipient heart transplant ; Any elective surgical procedure plan within 12 month index procedure ; Known illness serious clinical condition life expectancy &lt; 2 year ; Participation active followup phase clinicaltrial within 6 month ; Impossibility comply antiplatelet therapy study clinical followup ; Any impossibility comply protocol followup . Target lesion vessel angiographic evidence moderate severe calcification ; Presence severe tortuosity ; Presence severe angulation ( &gt; 60o ) ; Presence intraluminal thrombus ; Target lesion involve bifurcation ( side branch ≥2.0mm ) ; Target lesion locate leave main stem ; Aortoostial lesion location ; Target lesion involve side branch reference diameter≥2.0mm ; Presence significant stenosis ( &gt; 40 % ) target vessel either proximal distal target lesion untreated ; Previous placement stent within 10mm target lesion ; Total occlusion ( TIMI flow grade 0 1 ) ; Target lesion locate arterial vein graft ; Target lesion due instent restenosis ; Coronary anatomy unsuitable percutaneous treatment implantation available study stent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Optima</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Drug elute stent</keyword>
</DOC>